ÃØÃÜÑо¿Ëù

Internal Server Error
Unlock full details of this profile with our freeÌýLiteÌý±è±ô²¹²Ô!
Signup and get free access

Last updated:

About SR One

SR One is a venture capital firm founded in 1985. It is primarily based out of Redwood City, United States. As of Dec 2024, SR One is an active investor, having invested in 127 companies, with 4 new investments in the last 12 months. It primarily invests in Series B round in United States based startups. Its investments are spread across a wide range of sectors from Life Sciences to High Tech and HealthTech. Most recently it led the $42M Series B round of Nomic along with Amplitude. This round also saw participation from Lux Capital and other investors.
Overall, SR One portfolio has seen 22 IPOs and 53 acquisitions including key companies like Progyny, Alere and Spero Therapeutics. A lot of funds co-invest with SR One, with names like Novo Holdings sharing a substantial percentage of its portfolio.
SR One has team of 33 people including 7 partners.
Key Metrics
Team Members
, &
Portfolio Count
Portfolio Sectors
Portfolio Locations
Rounds of Entry
Series A, Series B &
Portfolio IPOs
Portfolio Acquisitions
Portfolio Soonicorns
Deals in last 12 months
Get SR One's portfolio delivered to your inbox!

SR One's Investment Trends by Stage

SR One has made 40 investments in Series A stage with an average round size of $36.6M, 35 investments in Series B stage with an average round size of $33.5M and 16 investments in Series C stage with an average round size of $78M.
Here are SR One's investment trends by stages:
Note: We have considered here, only first round of investments
Breakdown of SR One's investments by stage of entrySeries A (40)Series B (35)
Stage of entry
No. of Investments
Series A
40
Series B
35
Series C
16
Series D
8
Seed
4
Others
2

SR One's Investment Trends by Sector

SR One has a diverse portfolio, with companies operating in the Life Sciences, High Tech, HealthTech, Healthcare and Sustainability Tech. Notably, it has invested in 107 Tech companies, 84 Enterprise (B2B) companies, 8 Software companies and at least 6 companies focusing on Consumer (B2C).
Here are SR One's investment trends by sector:
Note: We have considered here, only first round of investments
Breakdown of SR One's investments by sectorsLife Sciences (88)High Tech (18)
Sector
No. of Investments
Life Sciences
88
High Tech
18
HealthTech
11
Healthcare
11
Sustainability Tech
11
Others
13

SR One's Investment Trends by Geography

SR One has made most investments in United States (91), followed by United Kingdom where it has made 17 investments.
Here are SR One's investment trends by geography:
Note: We have considered here, only first round of investments
Breakdown of SR One's investments by countriesUnited States (74)United Kingdom (14)
Country
No. of Investments
United States
74
United Kingdom
14
Israel
4
Switzerland
3
Canada
2
Others
9

SR One's recent investments

SR One has not made any investment in 2025 so far.
Here are the most recent investments by SR One:
Date
Company
Location
Round Details
Round Amount
Co-Investors
Dec 04, 2024
Denmark
Series A
$84.1M
Sep 17, 2024
Canada
Series B
$42M
Aug 08, 2024
United States
Series C
$112M
Jul 17, 2024
Japan
Series A
$38.2M
Jul 16, 2024
Switzerland
Series C
$100M
lockGet the detailed list of all investments by SR One. Download now!

IPOs and Publicly Listed companies in SR One's Portfolio

22 of SR One's portfolio companies have become public.ÌýZenas BioPharma got listed on the National Association of Securities Dealers Automated Quotations (NASDAQ), in Sep 2024 at marketcap of $676MÌýand Alumis got listed on the New York Stock Exchange (NYSE) at marketcap of $902M.
Here are SR One's portfolio companies that went public:
Company
IPO Date
First Invested on
First Round of Investment
Round Size
Sep 13, 2024
May 03, 2024
Series C
$200M
Jun 28, 2024
Mar 07, 2024
Series C
$259M
Feb 10, 2023
Jun 01, 2022
Series B
$118M
Sep 15, 2022
Aug 31, 2021
Series D
$55M
Feb 04, 2022
Oct 03, 2019
Series B
$85M

Acquired companies in SR One's Portfolio

53 companies from SR One's portfolio have been acquired.ÌýThe most recent acquisition were Morphic Therapeutic in Jul 2024Ìýby Lilly for $3.2B.
Here are SR One's portfolio companies that got acquired most recently:
Company
Acquisition Date
First Invested on
First Round of Investment
Round Size
Jul 08, 2024
Jun 30, 2016
Series A
$51.5M
Aug 21, 2023
Mar 25, 2014
Series B
$15M
Aug 10, 2023
Jan 13, 2017
Series B
$32.3M
Jan 19, 2023
-
-
-
Oct 24, 2022
Nov 15, 2012
Series B
$37.5M

Team profile of SR One

SR One has a team of 33 membersÌýincluding 7 Partners, 11 Venture Partners and 5 PrincipalsÌýlocated in United States, United Kingdom and . SR One's team sits on the board of 1 company.
Here is a list of top team members in SR One:
Name
Designation
Location
Board Memberships
Contact details
Partner
San Francisco
-
Partner
London
-
Partner
San Mateo
-
Partner
Los Altos
-
-
Partner
San Francisco
-
Partner
London
-
Partner
United States
-
Venture Partner
Switzerland
-
-
Venture Partner
San Francisco
-
Venture Partner
London
-
Venture Partner
San Francisco
-
-
lockGet the full list of SR One's team & partners for free. Download now!

Co-investors of SR One

Over the past 33 years, 644 investors have co-invested in SR One's portfolio companies.

  • Invested before SR One:ÌýAtlas Venture, Novo Holdings and 144 others have invested in rounds before SR One. There are 5 companies where Atlas Venture has invested before SR One and 5 companies where Novo Holdings has invested before SR One.
  • Top Co-investors of SR One:Ìý248 investors entered a company along with SR One. These include investors like Novo Holdings (8 companies).
  • Invested after SR One:ÌýA total of 250 investors have invested in SR One's portfolio after their investments. Top Investors include Orbimed (7 companies), RA Capital Management (6 companies) and Google Ventures (4 companies).
Get full list of SR One's co-investors delivered to your inbox!

Recent News related to SR One

•
FinSMEs•Jan 13, 2025•, Pivotal Life Sciences, Quan Capital, Qiming Venture Partners and 8 others
•
Seeking Alpha•Dec 30, 2024•Kala Pharmaceuticals, SR One, Cormorant Capital, Woodline Partners
•
Goodwin•Dec 14, 2024•Antag Therapeutics, Pictet Group, SR One, Versant Ventures and 5 others
•
Fierce Biotech•Dec 04, 2024•Novo Holdings, Antag Therapeutics, Versant Ventures, Long View Ventures and 5 others
•
Business Wire•Nov 18, 2024•Avenzo Therapeutics, VelaVigo, Orbimed, Foresite Capital and 13 others
•
Contract Pharma•Oct 31, 2024•Elektrofi, Novo Holdings, RA Capital Management, Royalty Pharma and 3 others
•
Financial Post•Sep 17, 2024•Nomic, Amplitude, AVANT BIO, Lux Capital and 2 others
•
Bakersfield•Sep 12, 2024•Oruka Therapeutics, Braidwell, Venrock, Fairmont and 18 others
•
BioWorld•Jul 17, 2024•Renalys, Catalys Pacific, SR One, JP Investment and 1 other
Unlock full details of this profile with our freeÌýLiteÌý±è±ô²¹²Ô!Signup and get free accessÌýarrow-right-long